What the FDA labels say about taking them together
Diclofenac and nabumetone
Diclofenac's FDA label (Licart) of April 2, 2026 names nabumetone in its drug interactions section; nabumetone's label does not name diclofenac itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The diclofenac label: “Concomitant use of LICART and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the diclofenac FDA label on DailyMed (effective February 11, 2025, Haleon US Holdings LLC); the nabumetone FDA label on DailyMed (effective January 13, 2025, ScieGen Pharmaceuticals Inc).
What does the diclofenac label say about nabumetone?
Licart label (IBSA Pharma Inc., April 2, 2026), drug interactionsPemetrexed Clinical Impact: Concomitant use of LICART and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). … regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
Source: FDA drug label (Licart, NDA206976), IBSA Pharma Inc., effective April 2, 2026 (SPL set 851c8b39-6056-4bbc-812e-b9b13977c1ac), via openFDA
Source: FDA drug label (Flector, NDA021234), IBSA Pharma Inc., effective October 21, 2025 (SPL set 1f19a016-c4fc-43c5-9990-e5f2e2776a82), via openFDA
Source: FDA drug label (Zipsor, NDA022202), Assertio Specialty Pharmaceuticals LLC, effective March 1, 2026 (SPL set ed2a8868-78eb-47b8-8f46-0f70e2891e07), via openFDA
Source: FDA drug label (Voltaren Arthritis Pain), Haleon US Holdings LLC, effective February 11, 2025 (SPL set 30a94282-0892-442a-aa10-6525cbd4fe88), via openFDA; the full label on DailyMed
What does the nabumetone label say about diclofenac?
Nabumetone's label does not name diclofenac itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Nabumetone label, boxed warningNSAIDs 1 cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Nabumetone label, boxed warningCardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
Source: FDA drug label (Nabumetone), ScieGen Pharmaceuticals Inc, effective January 13, 2025 (SPL set 80c6888d-03b4-44f3-b94d-bcf5154ceae5), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Diclofenac | Nabumetone | |
|---|---|---|
| Labeled for | Pain, Osteoarthritis, Rheumatoid arthritis, Migraine | Osteoarthritis, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0619 per tablet 75 mg tablet | $0.128 per tablet 500 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once